SQI Diagnostics, Isis Ink Immunogenicity Assay Development Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Toronto-based life sciences and diagnostics company SQI Diagnostics today announced a method development deal with Isis Pharmaceuticals.

The deal covers the development of a multiplexed assay using SQI's Ig Plex multiplexing immunogenicity technology. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.